Antifungal susceptibility against yeasts isolated from pediatric oncology patients

References

• Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161–189
   PubMed Web of Science ®Google Scholar
• Safdar A, Chaturvedi V, Cross EW, et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 2001; 45: 2129–2133
   PubMed Web of Science ®Google Scholar
• Nolte FS, Parkinson T, Falconer DJ, et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997; 41: 196–199
   PubMed Web of Science ®Google Scholar
• Marr KA, White TC, van Burik JA, et al. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997; 25: 908–910
   PubMed Web of Science ®Google Scholar
• Boschman CR, Bodnar UR, Tornatore MA, et al. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob Agents Chemother 1998; 42: 734–738
   PubMed Web of Science ®Google Scholar
• Krcmery V, Laho L, Huttova M, et al. Aetiology, antifungal susceptibility, risk factors and outcome in 201 fungaemic children: data from a 12-year prospective national study from Slovakia. J Med Microbiol 2002; 51: 110–116
   PubMed Web of Science ®Google Scholar
• Lyman CA, Garrett KF, Peter J, et al. Increased adherence of fluconazole-resistant isolates of Candida species to explanted esophageal mucosa. Eur J Clin Microbiol Infect Dis 1999; 18: 213–216
   Google Scholar
• Barchiesi F, Schimizzi AM, Fothergill AW, et al. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999; 18: 302–304
   PubMed Web of Science ®Google Scholar
• Laverdiere M, Hoban D, Restieri C, et al. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 2002; 50: 119–123
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, White TC, et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309–316
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325–1330
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–2029
   PubMed Web of Science ®Google Scholar
• Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard NCCLS document M27-A2. Wayne, PA; 2002.
   Google Scholar
• Rex JH, Cooper CR, Jr, Merz WG, et al. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995; 39: 906–909
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L, et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol 2003; 41: 2176–2179
   PubMed Web of Science ®Google Scholar
• Mullen CA, Abd El-Baki H, Samir H, et al. Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients. Support Care Cancer 2003; 11: 321–325
   PubMedGoogle Scholar
• MacDonald L, Baker C, Chenoweth C. Risk factors for candidemia in a children's hospital. Clin Infect Dis 1998; 26: 642–645
   PubMed Web of Science ®Google Scholar
• Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets 2006; 7: 495–504
   PubMed Web of Science ®Google Scholar
• Marr KA. Invasive Candida infections: the changing epidemiology. Oncology (Williston Park) 2004; 18: 9–14
   PubMedGoogle Scholar
• Bennett JE, Izumikawa K, Marr KA. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 2004; 48: 1773–1777
   PubMed Web of Science ®Google Scholar
• Safdar A, van Rhee F, Henslee-Downey JP, et al. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 2001; 28: 873–878
   PubMed Web of Science ®Google Scholar
• el-Mahallawy HA, Attia I, Ali-el-Din NH, et al. A prospective study on fungal infection in children with cancer. J Med Microbiol 2002; 51: 601–605
   PubMed Web of Science ®Google Scholar
• Chiou CC, Groll AH, Gonzalez CE, et al. Esophageal candidiasis in pediatric acquired immunodeficiency syndrome: clinical manifestations and risk factors. Pediatr Infect Dis J 2000; 19: 729–734
   Google Scholar
• Safdar A, Bannister TW, Safdar Z. The predictors of outcome in immunocompetent patients with hematogenous candidiasis. Int J Infect Dis 2004; 8: 180–186
   Google Scholar
• Zaoutis TE, Greves HM, Lautenbach E, et al. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004; 23: 635–641
   PubMed Web of Science ®Google Scholar
• Moreira-Oliveira MS, Mikami Y, Miyaji M, et al. Diagnosis of candidemia by polymerase chain reaction and blood culture: prospective study in a high-risk population and identification of variables associated with development of candidemia. Eur J Clin Microbiol Infect Dis 2005; 24: 721–726
   Google Scholar